|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Meta‐analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia显示文摘 | E. Dahl L. L. Gluud N. Kimer A. Krag | 2012 | Aliment Pharmacol Ther2012，，7： | 3 |
| 2 | Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients显示文摘AIM To develop a scale of domains associated with the health-related quality-of-life(HRQOL) in patients with cirrhosis-related ascites.METHODS We initially undertook literature searches and a qualitative study in order to design a cirrhosis-associated ascites symptom(CAS) scale describing symptoms with a potential detrimental impact on health related quality of life(HRQL)(the higher the score, the worse the symptoms). Discriminatory validity was assessed in a validation cohort including cirrhotic patients with(1) tense/severe;(2) moderate/mild; or(3) no ascites(controls). Patients also completed chronic liver disease questionnaire(CLDQ) and the Euro QoL 5-Dimensions 5-Level(EQ-5D-5L) questionnaire evaluating HRQL. The relation between scale scores was analysed using Spearman correlations. RESULTS The final CAS scale included 14 items. The equivalent reliability was high(Chronbach's alpha 0.88). The validation cohort included 103 patients(72% men, mean age 62.4 years). The mean scores for each question in the CAS scale were higher for patients with severe/tense ascites than for mild/moderate ascites and controls. Compared with controls(mean = 9.9 points), the total CAS scale score was higher for severe/tense ascites(mean = 23.8 points) as well as moderate/mild ascites(mean = 18.6 points)(P < 0.001 both groups). We found a strong correlation between the total CAS and CLDQ score(rho = 0.82, P < 0.001) and a moderate correlation between the CAS and the EQ-5D-5L score(0.67, P < 0.001). CONCLUSION The CAS is a valid tool, which reflects HRQOL in patients with ascites. | Agnete Nordheim Riedel Nina Kimer Anne-Sofie Houlberg Jensen Emilie Kristine Dahl Mads Israelsen Luise Aamann Lise Lotte Gluud | 2018 | World Journal of Gastroenterology2018，24，15： | 3 |
| 3 | Innovation paths and the innovation perfor- mance of low-technology firms: An empirical analysis of German industry显示文摘 | Kimer E | 2009 | Research Policy2009，38，5： | 1 |
| 4 | 查看详情显示文摘 | Blaser H.-U Burkhardt S Kimer H.J M(o)ssner T Studer M | | 0，，： | 1 |
| 5 | Synthesis of metal-azo dyes and their optical and thermal properties as recording materials for DVD-R显示文摘 | ParkH KimER KimDJ etal | 2002 | J Chem Soc Jpn2002，，75： | 1 |
| 6 | Meta - analysis: the safety and efficacy of vaptans ( tolvaptan, satavaptan and lix-ivaptan) in cirrhosis with ascites or hyponatraemia 显示文摘 | Dahl E Gluud LL Kimer N | 2012 | Ali- ment Pharmacol Ther2012，36，7： | 1 |
| 7 | Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C:systematic review and metaanalysis of randomised controlled trials显示文摘 | Kimer N Dahl EK Gluud LL | | 0，，05： | 1 |
| 8 | Non-R&D-Intensive Firms Innovation Sourcing显示文摘 | Oliver Som Eva Kimer Angela Jager | 2014 | Low-tech Innovation2014，，9： | 1 |
| 9 | Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature显示文摘 | Nina Kimer Martin Feineis S? ren M? ller Flemming Bendtsen | 2014 | Scandinavian Journal of Gastroenterology2014，，2： | 1 |
| 10 | Cancer risks and mortality in heterozygous ATM mutation carriers 显示文摘 | Thompson D Duedal S Kimer J | 2005 | J Natl Cancer Inst2005，97，11： | 1 |
| 11 | Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia显示文摘 | Dahl E Gluud LL Kimer N | 2012 | Aliment Pharmacol Ther2012，36，7： | 1 |
| 12 | The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy 显示文摘 | Lauridsen MM Thiele M Kimer N | 2013 | Metab Brain Dis2013，28，2： | 1 |
| 13 | Cancer risks and mortality in heterozygous ATM mutation carriers 显示文摘 | Thompson D Duedal S Kimer J | 2005 | J Natl Cancer Inst2005，97，11： | 1 |
| 14 | Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy显示文摘 | N. Kimer A. Krag S. M?ller F. Bendtsen L. L. Gluud | 2014 | Aliment Pharmacol Ther2014，，2： | 1 |
| 15 | Ki-67 expression in axiUary lymph node metastases in breast cancer is prognostically significant 显示文摘 | Tawfik K KiMer BF Davis MK | 2013 | Hum Pathol2013，44，1： | 1 |
| 16 | Radiocarbon dating organic residues at the microgram level显示文摘 | Kimer D L Burky R Taylor R E | | 0，，123： | 1 |
| 17 | Low and high temperature TiO2 oxygen sensors 显示文摘 | Kimer U Schierbaum K D Goepel W | 1990 | Sensors and Actuators B1990，1，： | 1 |
| 18 | New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state显示文摘 | Nina Kimer Jens Peter Goetze Flemming Bendtsen S?ren M?ller | 2014 | Eur J Clin Invest2014，，5： | 1 |
| 19 | Systematic review with meta-analysis:the effects of rifaximin in hepatic encepha- lopathy显示文摘 | Kimer N Krag A Moller S | 2014 | Aliment Pharmaeol Ther2014，40，2： | 1 |
| 20 | Functions encoded by pyrroinitrin biosynthesis genes from pseudomonas fluorescens显示文摘 | Kimer S Hammer P E Hill D S | 1998 | Journal of Bacteriology1998，180，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员